Loading…
vTv Therapeutics Inc. is projected to rise to $35.63 by 2027, a +6% move from its current price of $33.72. VTVT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $32.34 | $33.74 | $35.21 | +0.07% |
| May 30 | $31.79 | $33.77 | $35.87 | +0.14% |
| May 31 | $31.39 | $33.79 | $36.38 | +0.21% |
| Jun 1 | $31.05 | $33.82 | $36.82 | +0.28% |
| Jun 2 | $30.76 | $33.84 | $37.22 | +0.35% |
| Jun 3 | $30.51 | $33.86 | $37.59 | +0.42% |
| Jun 4 | $30.27 | $33.89 | $37.93 | +0.50% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $30.27 | $33.89 | $37.93 | +0.50% |
| Week 2 | $29.04 | $34.06 | $39.94 | +0.99% |
| Week 3 | $28.15 | $34.22 | $41.61 | +1.49% |
| Week 4 | $27.45 | $34.39 | $43.09 | +2.00% |
| Week 5 | $26.86 | $34.56 | $44.48 | +2.50% |
| Week 6 | $26.35 | $34.74 | $45.79 | +3.01% |
| Week 7 | $25.90 | $34.91 | $47.04 | +3.52% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program.
vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
VTVT is currently trading at $34.41 and operates in the Healthcare sector as a biopharmaceutical company focused on diabetes and chronic disease therapies. It holds a market cap of $135.51M and is ranked 4081 by market capitalization.
A major floor 30.4% below — a decisive break under it would weaken the trend.
The nearest floor, 12.8% below — buyers have tended to step in here.
The nearest ceiling, 20.0% above — a clean break opens room to run.
A major ceiling 35.2% above — clearing it would confirm fresh momentum.
Key VTVT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VTVT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $34.68 | Sell | $34.28 | Sell |
| MA 10 | $35.12 | Sell | $34.36 | Sell |
| MA 20 | $33.33 | Buy | $34.30 | Sell |
| MA 50 | $35.63 | Sell | $34.84 | Sell |
| MA 100 | $35.86 | Sell | $34.16 | Sell |
| MA 200 | $30.14 | Buy | $30.91 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.85 | Neutral |
| Stoch RSI (14) | 41.95 | Neutral |
| CCI (20) | 13.18 | Neutral |
| Williams %R (14) | -59.10 | Info |
| MACD (12,26,9) | 0.19 | Buy |
| ROC (12) | 9.91 | Buy |
| Bollinger %B (20,2) | 0.54 | Neutral |
| Stochastic %K (14) | 40.90 | Neutral |
| TRIX (15) | -0.16 | Sell |
| Awesome (5,34) | 0.14 | Buy |
| Ultimate (7,14,28) | 40.45 | Neutral |
| Momentum (10) | 1.61 | Buy |
| Aroon Osc (25) | -12.00 | Sell |
| Hull MA (9) | 33.50 | Buy |
| ADX (14) | 11.51 | Neutral |
| ATR (14) | 1.27 | Info |
The 30-day technical picture is bullish in sentiment. RSI(14) stands at 50, with a SMA50 of $35.72 and a SMA200 of $29.95. Near-term support is at $29.40 and resistance is at $40.45. The thirty-day range spans from $25.65 to $46.15, and annualized volatility is 90%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $29.02 | $33.72 | $43.87 | 0% | Neutral | |
| $26.72 | $35.63 | $51.10 | +6% | Neutral | |
| $26.27 | $36.65 | $55.34 | +9% | Neutral | |
| $25.99 | $37.68 | $59.23 | +12% | Neutral | |
| $30.08 | $45.15 | $73.39 | +34% | Bullish | |
| $35.78 | $55.46 | $92.83 | +64% | Bullish | |
| $40.07 | $64.02 | $109.98 | +90% | Bullish | |
| $39.35 | $64.71 | $113.81 | +92% | Bullish | |
| $36.88 | $62.36 | $112.05 | +85% | Bullish | |
| $36.33 | $63.11 | $115.66 | +87% | Bullish | |
| $55.38 | $109.26 | $217.41 | +224% | Bullish | |
| $86.68 | $192.61 | $430.93 | +471% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $29.02 | $33.72 | $39.74 | +0.00% |
| June 2026 | $28.73 | $34.16 | $41.88 | +1.30% |
| July 2026 | $29.85 | $35.96 | $45.01 | +5.29% |
| August 2026 | $29.28 | $35.65 | $45.32 | -0.86% |
| September 2026 | $28.07 | $34.47 | $44.38 | -3.32% |
| October 2026 | $28.28 | $35.01 | $45.60 | +1.58% |
| November 2026 | $28.15 | $35.09 | $46.16 | +0.23% |
| December 2026 | $26.32 | $33.04 | $43.87 | -5.86% |
Click any year to see its month-by-month VTVT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, VTVT is projected to trade between $29.02 and $43.87, averaging $33.72 — a potential gain of 0% from today's $33.72. A consolidation phase looks the most probable path here.
vTv Therapeutics Inc.'s 2027 outlook centres on $35.63, within a $26.72 to $51.10 range. That is up +6% on the projected 2026 average. That marks a +6% change versus current levels. Price action looks broadly range-bound.
By 2028, VTVT could reach as high as $55.34, with a base case around $36.65 and support toward $26.27 — roughly +9% from $33.72. A consolidation phase looks the most probable path here.
Expect VTVT to range from $25.99 to $59.23 through 2029. The $37.68 average target implies a +12% move from current prices. That is up +3% on the projected 2028 average. Price action looks broadly range-bound.
The VTVT price prediction for 2030 points to an average of $45.15 (low $30.08, high $73.39) — a potential gain of +34% on today's $33.72. Buyers look set to stay in control over this stretch.
In 2031, VTVT is projected to trade between $35.78 and $92.83, averaging $55.46 — a potential gain of +64% from today's $33.72. That is up +23% on the projected 2030 average. Momentum favours further upside here.
vTv Therapeutics Inc.'s 2032 outlook centres on $64.02, within a $40.07 to $109.98 range. That is up +15% on the projected 2031 average. That marks a +90% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, VTVT could reach as high as $113.81, with a base case around $64.71 and support toward $39.35 — roughly +92% from $33.72. Momentum favours further upside here.
Expect VTVT to range from $36.88 to $112.05 through 2034. The $62.36 average target implies a +85% move from current prices. That is -4% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The VTVT price prediction for 2035 points to an average of $63.11 (low $36.33, high $115.66) — a potential gain of +87% on today's $33.72. Momentum favours further upside here.
In 2040, VTVT is projected to trade between $55.38 and $217.41, averaging $109.26 — a potential gain of +224% from today's $33.72. That is up +73% on the projected 2035 average. Buyers look set to stay in control over this stretch.
vTv Therapeutics Inc.'s 2050 outlook centres on $192.61, within a $86.68 to $430.93 range. That is up +76% on the projected 2040 average. That marks a +471% change versus current levels. Momentum favours further upside here.
Investing $1,000 in VTVT today (≈ 29.655991 VTVT) could be worth
$5,712.13
+$4,712.13 (+471%) by 2050 · US Dollar
Based on the average projected VTVT price of $192.61 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VTVTwould be worth at today's price.
$1,000 invested in VTVT on May 27, 2025 (≈ 62.305299 VTVT) would be worth
$2,100.93
+$1,100.93 (+110.1%) today · 2.10× · US Dollar
Based on a VTVT entry price of $16.05 vs. today's $33.72.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $36.6 | $921.31 | -7.9% |
| 1 month ago | $29.4 | $1,146.94 | +14.7% |
| 3 months ago | $39.32 | $857.58 | -14.2% |
| 6 months ago | $26.7 | $1,262.92 | +26.3% |
| 1 year ago | $16.05 | $2,100.93 | +110.1% |
| All time (5.0y) ago | $96 | $351.25 | -64.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VTVT forecast.
Our base-case forecast reaches $67.00 around 2040.
Implied market cap at $67.00: $263.89M
The multi-year forecast shows bullish potential across the horizon, with notable milestones in 2030, 2040 and 2050. In 2030 the average forecast price is $47.25 with a min of $31.03 and a max of $77.84, yielding a forecast ROI of 37.3 and a bullish sentiment. In 2040 the average is $114.71 with a min of $56.26 and a max of $232.60, yielding a forecast ROI of 233.4 and a bullish sentiment.
In 2050 the average is $203.19 with a min of $91.44 and a max of $464.51, yielding a forecast ROI of 490.6 and a bullish sentiment. These figures illustrate substantial upside in the long run, but as with all forecasts they are estimates, not guarantees, and depend on a range of factors including market conditions and clinical development progress.
Tap a question to reveal the answer.
2030 avg: $47.25; min: $31.03; max: $77.84; ROI: 37.3; sentiment: BULLISH.
The long-range forecast shows BULLISH sentiment for 2030, 2040 and 2050 with higher average prices ($47.25, $114.71, $203.19) and ROIs (37.3, 233.4, 490.6). Near term (2026) is NEUTRAL with avg $34.41. These are estimates, not guarantees.
Yes. The 2050 forecast shows an average of $203.19 and a max of $464.51, with ROI 490.6, indicating potential to exceed $200 in the forecast horizon.
Sentiment: BULLISH. RSI(14) is 50. SMA50 is $35.72 and SMA200 is $29.95. Support: $29.40; Resistance: $40.45. Thirty-day range: $25.65 to $46.15.
Current price: $34.41. Market cap: $135.51M. Rank: 4081.
vTv Therapeutics Inc. Community Discussion
0Share your vTv Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.